BEAM:NASDAQ
Beam Therapeutics Inc
$29.03
arrow_downward
-1.29%(-0.38) 1D
$29.51
arrow_upward
+1.65% (+0.48)bedtimeAfter hours
Closed: Jun 12, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEAM...
Open
$29.46
High
$30.50
Low
$28.67
Mkt. cap
2.99B
Avg. vol.
1.98M
Volume
1.59M
52-wk high
$36.44
52-wk low
$15.60
EPS
-$0.64
Beta
2.25
Shares outstanding
102.88M
No. of employees
522
Open
$29.46
High
$30.50
Low
$28.67
Mkt. cap
2.99B
Avg. vol.
1.98M
Volume
1.59M
52-wk high
$36.44
52-wk low
$15.60
EPS
-$0.64
Beta
2.25
Shares outstanding
102.88M
No. of employees
522
Analyst outlook
Analyst Ratings
Based on 13 analysts giving stock ratings to BEAM in the past 3 months
Strong Buy
Buy
12
Hold
1
Sell
0
12 month forecast
Based on 13 Wall Street analysts offering 12 month price targets for BEAM in the last 3 months.
Highest
Current $29.03
$80.00 (+175.58%)
Average
$51.58 (+77.68%)
Lowest
$26.00 (-10.44%)
News stories
From sources across the web
Profile
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia
About Beam Therapeutics Inc
AI content may include mistakes. Learn more